{
  "id": "5a7612b483b0d9ea6600001d",
  "type": "yesno",
  "question": "Is enzastaurin effective treatment of glioblastoma?",
  "ideal_answer": "No. Enzastaurin does not improve prognosis of glioblastoma patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17620423",
    "http://www.ncbi.nlm.nih.gov/pubmed/26643807",
    "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
    "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
    "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
    "http://www.ncbi.nlm.nih.gov/pubmed/23911595",
    "http://www.ncbi.nlm.nih.gov/pubmed/20150385",
    "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
    "http://www.ncbi.nlm.nih.gov/pubmed/26692525",
    "http://www.ncbi.nlm.nih.gov/pubmed/21896554",
    "http://www.ncbi.nlm.nih.gov/pubmed/20044633"
  ],
  "snippets": [
    {
      "text": "RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR=1.24, p=0.056). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enzastaurin (LY317615) in combination with bevacizumab for recurrent malignant gliomas is well-tolerated, with response and progression-free survival similar to bevacizumab monotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26643807",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite promising phase II clinical trial results and patient benefit in terms of clinical improvement and longer progression-free survival, an overall survival benefit has not been demonstrated in four randomized phase III trials of bevacizumab or cilengitide in newly diagnosed glioblastoma or cediranib or enzastaurin in recurrent glioblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: PFS-6 missed the primary planned outcome of 55%. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OS (median, 74 weeks) and PFS (median, 36 weeks) results from the current trial were comparable to those from a prior phase II study using erlotinib and were significantly better than those from 2 other previous studies that used thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21896554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, antiangiogenic agents including enzastaurin, cediranib, bevacizumab, and others that target mainly the VEGF pathway, have been evaluated in this highly angiogenic disease. Among them, only bevacizumab has been associated with clear anti-tumor activity, although the lack of control studies limits the impact of the results to date.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Enzastaurin has anti-glioma activity in patients with recurrent high-grade glioma, but does not appear to have enough single-agent activity to be useful as monotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several signal transduction inhibitors have been examined in preclinical and clinical malignant glioma trials, including antiangiogenic agents (bevacizumab, enzastaurin), and inhibitors of epidermal growth factor receptor tyrosine kinase (gefitinib and erlotinib), mammalian target of rapamycin (temsirolimus, everolimus) and integrin (cilengitide). Although preliminary clinical results of the use of targeted agents have not translated into significantly better survival, more recent phase II trials are exploring the combination of multitargeted drugs with cytotoxic chemotherapy and radiotherapy in order to overcome the resistance of tumors to single-agent targeted therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20044633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several drugs have been tested, including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib and erlotinib), mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus), and vascular endothelial growth factor receptor (VEGFR), protein kinase C-beta, and other angiogenesis pathways inhibitors (vatalanib, bevacizumab, and enzastaurin). Although preliminary efficacy results of most trials in recurrent disease have fallen short on expectations, substantial advances have been achieved by associated translational research. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052640",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D005909",
    "http://www.biosemantics.org/jochem#4240085",
    "https://meshb.nlm.nih.gov/record/ui?ui=D016896"
  ],
  "exact_answer": "Yes"
}